Related Experiment Video
Updated: Aug 25, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment
Cassidy M Van Stiphout1, Anita K Luu1, Alicia M Viloria-Petit1
1Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Abstract:
Osteosarcoma (OS) is the most common type of bone cancer, with ~30% of patients developing secondary/metastatic tumors. The molecular complexity of tumor metastasis and the lack of effective therapies for OS has cultivated interest in exploiting the proteasome as a molecular target for anti-cancer therapy. As our understanding towards the behavior of malignant cells expands, it is evident that cancerous cells display a greater reliance on the proteasome to maintain homeostasis and sustain efficient biological activities. This led to the development and approval of first- and second-generation proteasome inhibitors (PIs), which have improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Researchers have since postulated the therapeutic potential of PIs for the treatment of OS. As such, this review aims to summarize the biological effects and latest findings from clinical trials investigating PI-based treatments for OS. Integrating PIs into current treatment regimens may better outcomes for patients diagnosed with OS.
Insights
Proteasome inhibitors (PIs) show therapeutic potential for osteosarcoma (OS) treatment. Integrating PIs into current regimens may improve outcomes for patients with this common bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma (OS) is the most common primary bone cancer.
- Metastasis occurs in ~30% of OS patients, highlighting the need for novel therapies.
- Cancer cells, including OS, exhibit increased dependence on the proteasome for survival and function.
Purpose of the Study:
- To review the biological effects of proteasome inhibitors (PIs) in osteosarcoma.
- To summarize recent clinical trial findings on PI-based treatments for OS.
- To explore the potential of PIs as a therapeutic strategy for osteosarcoma.
Main Methods:
- Literature review of preclinical studies on proteasome function in OS.
- Analysis of clinical trial data investigating proteasome inhibitors in OS patients.
- Synthesis of current research on the efficacy and safety of PIs for OS.
Main Results:
- Proteasome inhibitors have demonstrated anti-cancer activity in preclinical models of OS.
- Clinical trials are exploring the role of PIs in combination therapies for OS.
- Early findings suggest PIs may offer a new avenue for OS treatment.
Conclusions:
- The proteasome is a promising molecular target for osteosarcoma therapy.
- Proteasome inhibitors represent a potential addition to the current OS treatment landscape.
- Further clinical investigation is warranted to establish the efficacy of PIs in OS management.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:56Treatment Resistant Cancers